Cancer immunotherapy

Vaccine production
#BioNTech #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Moderna #mRNA #mRNA-based vaccines #Personalised medicine #UK government

New UK partnership to accelerate mRNA research

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines.  Professor Uğur Şahin, Chief Executive… Read More

#Business & Investment #Cancer Research #News #Trending News

#Cancer immunotherapy #Cancer research #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies

This week in drug discovery (2-6 January)

News round-up for 2-6 January by DDW Digital Content Editor Diana Spencer. The drug discovery industry has hit the ground running in 2023 with some big announcements in the first week, particularly in cancer research, where there has been good news in pancreatic, urothelial and uveal cancers. … Read More

#News

Cancer research
#Cancer immunotherapy #Cancer research #Funding #Immunotherapy #Investment #ISA Pharmaceuticals #Oncology #Ophthalmology #Synthetic biology

$5 million to fund trial of therapy for uveal melanoma

Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA Pharmaceuticals’ PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.  Cancer Focus Fund was established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and… Read More

#Business & Investment #Cancer Research #News

Pancreatic cancer
#Antibodies #Cancer immunotherapy #Cancer research #Immunotherapy #Oncology #Pancreatic cancer #Preclinical investigations

Triple immunotherapy eliminates pancreatic tumours

A novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, has significantly improved anti-tumour responses in preclinical models of pancreatic cancer.  In the study, published in Nature Cancer, researchers at The University of Texas MD Anderson Cancer Center… Read More

#Cancer Research #Editor's Choice #News

Testing acidity in the lab
#Cancer immunotherapy #Cancer research #Cancer treatment #Cytokines #Immunotherapy #Tumours

Acid discovery raises hopes of improved immunotherapies

The acidity of tumours impairs the effectiveness of anti-cancer therapies, according to a new study that could lead to a new generation of immunotherapy treatments.  Tumours have a more acidic environment (pH 6.5) than normal, healthy tissues (pH 7.2). New research has shown for the first time… Read More

#Cancer Research #News

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

Listen now: Last episode of DDW Highlights for 2022

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The focus has been on immunotherapy and genetics this week, with exciting… Read More

#News

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

This week in drug discovery (12-16 December)

News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia.  The top stories: … Read More

#News

Scientist in laboratory
#Antibodies #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Janssen #Leukaemia #Myeloma #Oncology

New trial data revealed in potential myeloma and leukaemia treatments

Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia.  The findings were presented at the American Society of Hematology (ASH) 2022 Annual Meeting taking place in New Orleans, US.  Along with positive Phase… Read More

#Cancer Research #News

Pedro Correa de Sampaio and Annelise Soulier
#Cancer immunotherapy #Cancer research #Financing #Start-ups

Start-up raises £520K to improve immunotherapy outcomes

Neobe Therapeutics, an early-stage startup, has raised £520K ($628,000) in equity funding to engineer live biotherapeutics to remove barriers to immune infiltration in solid tumours.  While immunotherapies have revolutionised the treatment of cancer, the large majority of patients with solid tumours (up to 85%) still do not… Read More

#News #Start-up Zone

#AI #Cancer #Cancer drug targets #Cancer immunotherapy #Cancer research #Immunotherapy #Oncology #The Institute of Cancer Research #The Royal Marsden NHS Foundation Trust

Scientists will target cancer’s ecosystems under new strategy

Cancer is supported by complex ecosystems within the body which can be disrupted by cutting-edge new treatments and cures, cancer researchers have concluded.  The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have revealed plans to direct research against the cells, signals and… Read More

#Cancer Research #News

T cells attacking cancer
#Cancer #Cancer immunotherapy #Cell and gene therapy #Cell therapy #HER2 #Immunotherapy #Oncology #Precision medicine #T-Cells #Tumours

Positive interim data for cell therapy in solid tumours

Triumvira Immunologics has revealed positive clinical data from its ongoing TACTIC‑2 Phase I/II trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumours.  These interim data demonstrate that TAC01-HER2 is well-tolerated and clinical activity was observed in the two higher dosing cohorts,… Read More

#Cancer Research #News

Monoclonal antibodies
#Cancer #Cancer immunotherapy #Cancer research #Monoclonal antibodies #Oncology #Phase I trial

Phase I trial of lead antibody candidate launched

DynamiCure has dosed the first patients in its Phase I clinical trial evaluating the first of the company’s two anti-CD93 monoclonal antibody candidates, DCBY02, in adults with a wide range of advanced cancers.  CD93 is a novel target downstream of VEGF-A (vascular endothelial growth factor) that has been shown… Read More

#Cancer Research #News

T cells attacking cancer
#Cancer #Cancer immunotherapy #Cancer research #Cancer vaccine #National Institute of Allergy and Infectious Diseases #Oncology #T-Cells

Experimental cancer vaccine shows promise in animal studies 

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.    The researchers found that intravenous (IV) administration of the vaccine… Read More

#Cancer Research #News

Basel map
#Biologics / Biotechnology #Cancer immunotherapy #Immuno-oncology #Market reporting #Oncology #Start-ups

Basel: a centre for ground-breaking oncology 

Listen to this article on the DDW podcast: Dr Stephan Emmerth and Paul Eschmann, Basel Area Business & Innovation, explain the benefits of being based in Basel – the talent pool, global players, academic institutions and investors, for example.  Companies specialising in oncology R&D and therapeutics continue to spring up all… Read More

#Exclusive Content #Market Reports

Breast cancer
#Breast cancer #Breast Cancer Now #Cancer immunotherapy #Cancer research #King's College London #Oncology #The Institute of Cancer Research

Immune targets identified for chemo-resistant breast cancers

Researchers from King’s College London and The Institute of Cancer Research, London, have performed a deep dive into the different immune markers within tumour tissue and blood samples of early breast cancer patients whose cancer failed to respond to chemotherapy given to them prior to surgery. The research gives insight… Read More

#Cancer Research #News